Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31.03.2026

Revenue growth above 20%Profit growth above 25%Results restatedRelated-party transactionsResults View source PDF Explain this filing

JGCHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.8%Reaction day

₹418.00

prior close

₹415.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.4%-5.5% vs market

Commodity Chemicals peers, median of 50sector-0.6%-5.2% vs sector

On the reaction day the stock moved 5.5 pts less than Nifty Microcap 250 and 5.2 pts less than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.9

10m

-4.8

15m

-4.6

30m

-3.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.8-0.4-5.5-0.6-5.2

Next day

-7.2-1.7-5.5-1.7-5.5

-7.4-1.3-6.1-1.2-6.2

-5.3-0.7-4.6-0.1-5.2

-6.3+0.4-6.7-0.8-5.4

-5.5+0.5-6.0-0.8-4.7

-1.9+2.8-4.7-0.0-1.8

15d

+1.7+1.2+0.5-3.1+4.8

+2.0+5.3-3.3-3.1+5.1

+6.4+9.9-3.5-4.9+11.3

+43.9+13.1+30.8-3.2+47.2

UpDownMarket · Nifty Microcap 250Sector · Commodity Chemicals peers, median of 50Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

J.G. Chemicals reported mixed results for FY2026. Consolidated revenue grew 14.7% to Rs 972.9 crore from Rs 848 crore, driven by the subsidiary BDJ Oxides. However, standalone revenue grew only 6.3% to Rs 288.9 crore. Consolidated PAT increased marginally by 1.9% to Rs 67.6 crore, while standalone PAT declined 8% to Rs 26.4 crore. EPS improved on consolidated basis to Rs 17.08 from Rs 16.34. The board recommended a dividend of Rs 1.10 per share (11%). Auditors issued unmodified opinions for both standalone and consolidated results. Rs 42.62 million of IPO proceeds for R&D Centre remains unutilized and will be deployed in FY2027 due to construction delays.

Likely market impact

Positive revenue growth and maintained profitability signal stable operations, though the standalone PAT decline warrants monitoring. The dividend payment and strong EPS indicate returns to shareholders despite margin pressures.